{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:17:24Z","timestamp":1775881044231,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7023,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1023\/a:1008375016038","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"1289-1294","source":"Crossref","is-referenced-by-count":57,"title":["Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"C.","family":"Linassier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Calais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Letortorec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Br\u00e9mond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Delain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-T.","family":"Georget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Raban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Leloup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Binet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Lamagn\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008375016038_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(87)92744-9","article-title":"Risk of therapy-related leukaemia and preleukaemia after Hodgkin\u2019s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy","volume":"2","author":"Pedersen-Bjergaard","year":"1987","journal-title":"Lancet"},{"key":"10.1023\/A:1008375016038_bb0010","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008375016038_bb0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jnci\/78.3.459","article-title":"Leukemia after therapy with alkylating agents for childhood cancer","volume":"78","author":"Tucker","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008375016038_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1986.4.3.325","article-title":"Clinical and cytogenetic correlations in 63 patients with therapy-related myelo-dysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes n. 5 and 7","volume":"4","author":"Le Beau","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0025","first-page":"435","article-title":"Therapy-related leukemia and myelodysplastic syndrome","volume":"14","author":"Kantarjian","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008375016038_bb0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/1097-0142(19860815)58:4<924::AID-CNCR2820580420>3.0.CO;2-Y","article-title":"The association of specific \u2018favorable\u2019 cytogenetic abnormalities with secondary leukemia","volume":"58","author":"Kantarjian","year":"1986","journal-title":"Cancer"},{"key":"10.1023\/A:1008375016038_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0140-6736(91)90490-G","article-title":"Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours","volume":"338","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Lancet"},{"key":"10.1023\/A:1008375016038_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJM198907203210302","article-title":"Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia","volume":"321","author":"Pui","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008375016038_bb0045","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/1097-0142(19890615)63:12<2505::AID-CNCR2820631224>3.0.CO;2-Z","article-title":"Favorable cytogenetic abnormalities in secondary leukemia","volume":"63","author":"Fenaux","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1008375016038_bb0050","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.1992.10.9.1444","article-title":"Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxo-rubicin and cisplatin or cyclophosphamide for breast cancer","volume":"10","author":"Pedersen-Bjergaard","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary leukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1023\/A:1008375016038_bb0060","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.1998.16.5.1897","article-title":"Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors","volume":"16","author":"Pedersen-Bjergaard","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1023\/A:1008375016038_bb0070","series-title":"An International System for Human Cytogenetic Nomenclature","author":"Harnden","year":"1985"},{"key":"10.1023\/A:1008375016038_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1023\/A:1008375016038_bb0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0006-2952(92)90577-6","article-title":"Cellular uptake and tubulin binding properties of four Vinca alkaloids","volume":"43","author":"Singer","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1023\/A:1008375016038_bb0085","first-page":"103","article-title":"VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity","volume":"7","author":"Loike","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008375016038_bb0090","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnci\/83.14.1013","article-title":"Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer","volume":"83","author":"Andersson","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008375016038_bb0095","series-title":"The Chemotherapy Source Book","first-page":"689","article-title":"Second malignancies after chemotherapy","author":"Kyle","year":"1992"},{"key":"10.1023\/A:1008375016038_bb0100","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1992.10.9.1430","article-title":"Therapy-related acute promyelocytic leukemia: A report on 16 cases","volume":"10","author":"Detourmignies","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.leu.2400853","volume":"12","author":"Archimbaud","year":"1998","journal-title":"Leukemia"},{"key":"10.1023\/A:1008375016038_bb0110","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.leu.2401021","article-title":"Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalitie. EU Concerted Action 11q23 Workshop","volume":"12","author":"Seeker-Walker","year":"1998","journal-title":"Leukemia"},{"key":"10.1023\/A:1008375016038_bb0115","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.1998.16.5.1890","article-title":"Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYHU genes in therapy-related acute myeloid leukemia: Rare events related to DNA-topoisomerase II inhibitors?","volume":"16","author":"Dissing","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0120","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V76.6.1083.1083","article-title":"Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia","volume":"76","author":"Pedersen-Bjergaard","year":"1990","journal-title":"Blood"},{"key":"10.1023\/A:1008375016038_bb0125","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/0006-2952(85)90275-8","article-title":"Interactions of antitumor agents Ametantrone and Mitoxantrone (Novantrone) with double-stranded DNA","volume":"34","author":"Kapuscinski","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1023\/A:1008375016038_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00273412","article-title":"Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine","volume":"22","author":"Heinemann","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008375016038_bb0135","first-page":"4915","article-title":"Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene","volume":"45","author":"Bowden","year":"1985","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008375016038_bb0140","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"key":"10.1023\/A:1008375016038_bb0145","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19900601)65:11<2460::AID-CNCR2820651110>3.0.CO;2-S","article-title":"High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer","volume":"65","author":"Andersson","year":"1990","journal-title":"Cancer"},{"key":"10.1023\/A:1008375016038_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0925-5710(97)00108-4","article-title":"A case of therapy-related acute myeloblasts leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide","volume":"67","author":"Takeda","year":"1998","journal-title":"Int J Hematol"},{"key":"10.1023\/A:1008375016038_bb0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/oxfordjournals.annonc.a010725","article-title":"Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin","volume":"7","author":"Cremin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008375016038_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199309054742","article-title":"Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: Report of four additional cases and brief commentary","volume":"11","author":"Bredeson","year":"1993","journal-title":"Leuk Lymph"},{"key":"10.1023\/A:1008375016038_bb0165","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.1993.11.12.2370","article-title":"Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature","volume":"11","author":"Quesnel","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008375016038_bb0170","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/oxfordjournals.annonc.a059316","article-title":"Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature","volume":"6","author":"Hoffmann","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008375016038_bb0175","first-page":"1990","article-title":"Epipodophyllotoxin-related acute myeloid leukemia: A study of 35 cases","volume":"9","author":"Pui","year":"1995","journal-title":"Leukemia"},{"key":"10.1023\/A:1008375016038_bb0180","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<1049::AID-CNCR24>3.0.CO;2-0","article-title":"Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia","volume":"79","author":"Sandler","year":"1997","journal-title":"Cancer"},{"key":"10.1023\/A:1008375016038_bb0185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.leu.2400632","article-title":"Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus","volume":"11","author":"Stanulla","year":"1997","journal-title":"Leukemia"},{"key":"10.1023\/A:1008375016038_bb0190","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood.V92.10.3793","article-title":"An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region","volume":"92","author":"Strissel","year":"1998","journal-title":"Blood"},{"key":"10.1023\/A:1008375016038_bb0195","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.leu.2401570","article-title":"Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage","volume":"13","author":"Gieseler","year":"1999","journal-title":"Leukemia"},{"key":"10.1023\/A:1008375016038_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-4608(91)90246-Q","article-title":"Two different classes of therapy-related and de novo acute myeloid leukemia?","volume":"55","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419556642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419556642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/10\/1289\/19477836\/11-10-1289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:20:49Z","timestamp":1582183249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419556642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S0923753419556642"],"URL":"https:\/\/doi.org\/10.1023\/a:1008375016038","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}